Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Discontinuation of Antibiotics vs Standard Management in Elderly Hospitalized for Viral Respiratory Infection
2024-515695-13-00Phase 4Authorised
- Sponsor
- CHU Amiens-Picardie
- Start
- Feb 2025
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ceftriaxone, amoxicillin + clavulanate, piperacillin + tazobactam and pristinamycin in pulmonary infection (2 arms), sponsored by CHU Amiens-Picardie. Primary endpoint: Number of days without antibiotics at day 30. Planned start Feb 2025; status: authorised.
02
Drugs
ceftriaxoneamoxicillin + clavulanatepiperacillin + tazobactampristinamycin
03
Conditions
pulmonary infection
Beyond the preview
Go deeper on 2024-515695-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515695-13-00.